Dynamic IPSS-plus risk stratification for primary myelofibrosis.
Calculated Interpretation
Low Risk
0 Factors
Low-risk myelofibrosis profile.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Dynamic IPSS-plus risk stratification for primary myelofibrosis.
Section 2
Formula & Logic
Clinical Inputs
Age > 65
Binary clinical feature
Constitutional symptoms
Binary clinical feature
Hemoglobin < 10 g/dL
Binary clinical feature
WBC > 25 x10^9/L
Binary clinical feature
Peripheral blasts >= 1%
Binary clinical feature
Platelets < 100 x10^9/L
Binary clinical feature
RBC transfusion dependent
Binary clinical feature
Unfavorable karyotype
Binary clinical feature
Section 3
Pearls/Pitfalls
Result Bands
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
Dynamic IPSS-plus risk stratification for primary myelofibrosis.
OpiCalc Medical Oncology Module • Myeloma & MPN. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
DIPSS-Plus (Myelofibrosis) is included in the oncology module as a structured decision-support tool for myeloma & mpn workflows.
